In this final video of a four-part video series, Signify Health senior vice president of Episodes of Care, François de Brantes, speaks with Managed Healthcare Executive about value-based care, the toxic incentives in healthcare, how the Direct Contracting Model differs from Medicare Advantage and more.
Especially during the COVID-19 pandemic, healthcare systems and a variety of other healthcare entities have been sending lots of text messages to patients. Reminders about appointment, prompts to take medications, health information updates — they are part of healthcare’s new enthusiasm for all things digital and remote.
In this third of a four-part video series, Signify Health senior vice president of Episodes of Care, François de Brantes, speaks with Managed Healthcare Executive about value-based care, the toxic incentives in healthcare, how the Direct Contracting Model differs from Medicare Advantage and more.
Diagnoses spike in people's 65th year when most Americans become newly eligible for Medicare coverage.
In this second of a four-part video series, Signify Health senior vice president of Episodes of Care, François de Brantes, speaks with Managed Healthcare Executive about value-based care, the toxic incentives in healthcare, how the Direct Contracting Model differs from Medicare Advantage and more.
Although smoking is the predominate risk factor for lung cancer, about 1 in 5 cases cases are believed to be linked to genetic factors.
If replicated in future studies, the findings have important implications for the millions of people living with HIV, many of which display signs of residual viral replication despite treatment.
Samitt announced he is retiring after three years at the helm of the Minnesota Blues plan.
In this first of a four-part video series, Signify Health senior vice president of Episodes of Care, François de Brantes, speaks with Managed Healthcare Executive about value-based care, the toxic incentives in healthcare, how the Direct Contracting Model differs from Medicare Advantage and more.
One year into the COVID-19 pandemic and healthcare leaders are taking a hard look at all operations – especially innovative reimbursement models that best meet the needs of their business, providers and patients. No doubt these leaders are finally paying closer attention to value-based care.
In this month's episode of the Meet the Board podcast series, MHE spoke with Signify Health's Senior Vice President of Episodes of Care, François de Brantes. In the discussion de Brantes touched on a few facts about himself, he shared the toxic incentives in healthcare, how the Direct Contracting Model differs from Medicare Advantage and more.
Insurers might benefit from increase in the number of beneficiaries in their Medicare Advantage plans.
Bristol Myers Squibb and bluebird bio’s Abecma is the first B-cell maturation antigen (BCMA)-directed CAR-T cell immunotherapy for relapsed or refractory multiple myeloma after 4 or more prior lines of therapy.
Analysis also shows higher proportion of low- and modest-income beneficiaries in Medicare Advantage than Traditional Medicare.
Precision medicine may mean smaller clinical trials. Collecting real-world data can help supply some of the same information as a control group.
Since the start of the COVID-19 pandemic, a lot of progress has been made toward a better future, but it’s clear there’s still significant room for improvement. While progress is made in one area, other issues that live beneath the surface bubble up. That’s certainly the case for the current state of mental health.
The Minnesota PBM says it will pay $40 for a single-dose vaccine and $80 for a two-dose one. The company says it has paid pharmacies a total of $29 million in COVID-19 vaccine administration fees so far.
If we look for the silver linings among lessons learned in 2020, the brightest positive outcome may be a better coordinated and more robust investment in public health. Yet as we continue to fight COVID-19 in the U.S., it’s important not to lose sight of another incredibly important battle we face on the public health front: maternal health.
In this final part of a two-part video series, Senior Editor Peter Wehrwein spoke with Vayong Moua, the Director of Racial and Health Equity Advocacy for Blue Cross and Blue Shield of Minnesota (BCBSMN), about healthcare equity issues, how they relate to access issues, the political determinants of health and killing of George Floyd.
New Jersey and Pennsylvania are the latest to set up state-based exchanges. Kentucky, Maine, New Mexico and Virginia, which currently have hybrid state-federal programs, are expected to be next.
City of Hope researchers find longer overall survival rates among nonsmall cell lung cancer patients (NSCLC) who are immigrants. Could this be another instance of the healthy immigrant paradox?
In this first part of a two-part video series, Senior Editor Peter Wehrwein spoke with Vayong Moua, the Director of Racial and Health Equity Advocacy for Blue Cross and Blue Shield of Minnesota (BCBSMN), about healthcare equity issues, how they relate to access issues, the political determinants of health and killing of George Floyd.
The advent of checkpoint inhibitors has altered the treatment landscape in urothelial bladder cancer, said Arlene O. Siefker-Radtke, MD, during last week’s NCCN Conference.
Electronic prior authorizations (ePA) can significantly reduce the time between a request for prior authorization and a decision and the time to a patient receiving care. These were two of the top findings from an initiative launched by America’s Health Insurance Plans (AHIP) to better understand the impact of ePA on the prior authorization process.
There are significant risks patients face when they enroll in non-compliant and substandard health insurance products. A new report published by 30 patient organizations shares the risks and details ways state and federal lawmakers can help protect these vulnerable consumers.
MHE's Associate Editor Briana Contreras spoke with Senior Vice President of healthcare services at SCAN Health Plan, Eve Gelb. The two discussed the issue of vaccine mistrust among family caregivers and how it can result in leaving vulnerable seniors at risk.
Prior to the COVID-19 pandemic, telehealth was more of a stretch goal than a reality for most providers despite the seeming prevalence of video conferencing.
The agency also gave the green light to Zegalogue, an injectable treatment for severe hypoglycemia.
